# GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

> **NCT00495846** · PHASE2,PHASE3 · COMPLETED · sponsor: **Federico II University** · enrollment: 25 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Octreotide-LAR, Lanreotide Autogel
- **OTHER:** Locoregional treatments

## Key facts

- **NCT ID:** NCT00495846
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-04
- **Final completion:** 2008-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2009-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495846, "GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00495846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*